Northern Trust
GANX icon

Northern Trust’s Gain Therapeutics GANX Stock Holding History

Northern Trust’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Buy
113,997
+11,996
+12% +$26.1K ﹤0.01% 3914
2025
Q4 		$328K Buy
102,001
+13,602
+15% +$36.3K ﹤0.01% 3801
2025
Q3 		$156K Sell
88,399
-11,771
-12% -$19.9K ﹤0.01% 4046
2025
Q2 		$180K Hold
100,170
– – ﹤0.01% 3970
2025
Q1 		$191K Buy
100,170
+15,584
+18% +$34.6K ﹤0.01% 3958
2024
Q4 		$183K Buy
84,586
+39,642
+88% +$79.6K ﹤0.01% 4018
2024
Q3 		$80K Hold
44,944
– – ﹤0.01% 4108
2024
Q2 		$57.5K Sell
44,944
-1,542
-3% -$4K ﹤0.01% 4188
2024
Q1 		$175K Buy
46,486
+2,973
+7% +$12.3K ﹤0.01% 3938
2023
Q4 		$142K Buy
43,513
+30,236
+228% +$84.1K ﹤0.01% 4019
2023
Q3 		$43.5K Hold
13,277
– – ﹤0.01% 4199
2023
Q2 		$59.5K Hold
13,277
– – ﹤0.01% 4175
2023
Q1 		$64K Buy
13,277
+731
+6% +$2.99K ﹤0.01% 4201
2022
Q4 		$39.3K Hold
12,546
– – ﹤0.01% 4341
2022
Q3 		$41K Buy
+12,546
New +$47.1K ﹤0.01% 4378

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust's GANX Position: Q1 2026 in Review

Northern Trust increased its Gain Therapeutics (GANX) stake by 12% in Q1 2026, buying an estimated $26.1K and bringing the position to 113,997 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #3914.

Northern Trust first reported a position in GANX in Q3 2022 and has held it in 15 quarters since. The position peaked at $328K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Northern Trust held 113,997 shares of Gain Therapeutics worth $221K as of Q1 2026.
  • Northern Trust bought 11,996 Gain Therapeutics shares in Q1 2026, an estimated $26.1K.
  • Gain Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3914 holding.
  • Northern Trust first reported a position in Gain Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Northern Trust's Gain Therapeutics position peaked at $328K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.